Nanolynx Biologics is developing conditionally active nanobody-drug conjugates (CA-NDCs), a new class of cancer medicines designed for tumor-selective activation, deep tissue penetration, and reduced systemic toxicity. Powered by our proprietary IntelliBody™ platform, we overcome the fundamental biological and safety limitations of conventional ADCs, enabling a wider therapeutic window and improving outcomes for patients with hard-to-treat solid tumors.
